A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants with Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic DermatitisEczema
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 1000
- Registration Number
- NCT06815380
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Dermatitis, AtopicEczema
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 520
- Registration Number
- NCT06526182
- Locations
- 🇪🇸
Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
🇪🇸Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸Hospital Universitario ClÃnico San Cecilio, Granada, Spain
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
- Conditions
- Autoimmune DiseaseHealthy Volunteers
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 72
- Registration Number
- NCT06488209
- Locations
- 🇺🇸
Doral Medical Research, Miami, Florida, United States
🇺🇸Jennifer Parish, MD, Philadelphia, Pennsylvania, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06488170
- Locations
- 🇨🇿
University Hospital Ostrava, Ostrava, Czechia
🇨🇿Fakultnà nemocnice Plzeň, with its registred seat at Edvarda Beneše, Pilsen, Czechia
🇨🇿University Hospital in Motol, Praha, Czechia
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 92
- Registration Number
- NCT06200597
- Locations
- 🇺🇸
ICON Phase 1 unit Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
- Conditions
- Keratosis, Actinic
- Interventions
- Other: Vehicle ointment
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 280
- Registration Number
- NCT06135415
- Locations
- 🇩🇪
Site 17, Augsburg, Germany
🇩🇪Site 1, Bad Bentheim, Germany
🇩🇪Site 3, Bochum, Germany
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 110
- Registration Number
- NCT06029257
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Styria, Austria
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06030076
- Locations
- 🇦🇹
Gesundheitszentrum Citypark Graz, Graz, Styria, Austria
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 240
- Registration Number
- NCT05990725
- Locations
- 🇳🇱
Site 41, Utrecht, Netherlands
🇬🇧Site 38, Leeds, United Kingdom
🇬🇧Site 14, York, United Kingdom
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT05916365
- Locations
- 🇩🇪
Investigator Site 11, Münster, Nordrhein-Westfalen, Germany
🇩🇪Investigator Site 7, Darmstadt, Hessen, Germany
🇩🇪Investigator Site 9, Osnabrück, Lower Saxony, Germany